Krebs Biochemicals and Industries enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
128————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.10.10.10.10.1
225225212193183
352————
225225212193183
₹163.37————
54.262.166.074.283.8
414.8%362.2%321.7%260.6%218.7%
0.64×————
13.12×————
−210.61×————
−43.67×————
Reference items — trailing FY values
26.923.743.350.452.1
−1.7−5.5−15.0−8.7−15.8
−8.1−11.9−21.7−15.5−22.3
—−1.9−7.92.3−26.5
−5.9−5.9−13.0−5.5−37.4
—−5.9−13.0−5.5−37.4
—4.05.17.810.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KREBSBIO₹59.15

Krebs Biochemicals and Industries Limited

· Pharma & Health
₹ CrorePeersALPABALPHARMAVINEETLABNATCAPSUQBIOFILCHEMNECLIFEMANGALAMAAREYDRUGSMcap ₹128 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————127.5
- Cash, Equiv & ST Investments0.10.10.10.10.1
+ Total Debt183.2193.4212.2224.8224.8
Enterprise Value————352.2
Net Debt (memo)183.2193.3212.1224.7224.7
EV per Share————163.37
Total Capital83.874.266.062.154.2
Total Debt/Total Capital218.73260.64321.68362.15414.83
Total Debt/EV————0.64
EV/Sales————13.12
EV/EBITDA————-210.61
EV/EBIT————-43.67
Reference Items — Trailing FY Values
Sales52.150.443.323.726.9
EBITDA-15.8-8.7-15.0-5.5-1.7
EBIT-22.3-15.5-21.7-11.9-8.1
Operating Cash Flow-26.52.3-7.9-1.9—
Free Cash Flow-37.4-5.5-13.0-5.9-5.9
FCFF (free cash flow to the firm)-37.4-5.5-13.0-5.9—
Capital Expenditure10.97.85.14.0—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.